Search results
Results from the WOW.Com Content Network
Axonics' products, such as Axonics R20 and Axonics F15, are used to deliver sacral neuromodulation therapy, which Medical device maker Boston Scientific to buy Axonics for $3.7 billion Skip to ...
A sacral nerve stimulator is a small device usually implanted in the buttocks of people who have problems with bladder and/or bowel control. [1] [2] This device is implanted in the buttock and connected to the sacral nerve S3 by a wire. [3] The device uses sacral nerve stimulation to stop urges to defecate and urinate by sending signals to the ...
The end effect is a "normalization" of a neural network function from its perturbed state. Presumed mechanisms of action for neurostimulation include depolarizing blockade, stochastic normalization of neural firing, axonal blockade, reduction of neural firing keratosis, and suppression of neural network oscillations. [2]
Neurostimulation technology can improve the life quality of those who are severely paralyzed or have profound losses to various sense organs, as well as for permanent reduction of severe, chronic pain which would otherwise require constant (around-the-clock), high-dose opioid therapy (such as neuropathic pain and spinal-cord injury).
For premium support please call: 800-290-4726 more ways to reach us
A transcutaneous electrical nerve stimulation (TENS or TNS) is a device that produces mild electric current to stimulate the nerves for therapeutic purposes.TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation, but the term is often used with a more restrictive intent, namely, to describe the kind of pulses produced by portable ...
Responsive neurostimulation device is a medical device that senses changes in a person's body and uses neurostimulation to respond in the treatment of disease. The FDA has approved devices for use in the United States in the treatment of epileptic seizures [ 1 ] and chronic pain [ 2 ] conditions.
The original title incorrectly stated that the device is implantable On Monday, Nexalin Technology, Inc. (NASDAQ:NXL) announced the publication of a study in the Journal of Alzheimer’s Disease.